Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069992 | 0.85 | CRH (0.53) | CRHCRHR1 | |
| SCHEMBL6069631 | 0.82 | CRHR1 (0.47) | CRHCRHR1 | |
| SCHEMBL6070559 | 0.80 | CRHR1 (0.55) | CRHCRHR1 | |
| SCHEMBL6496629 | 0.78 | CRHR1 (0.41) | CRHCRHR1 | |
| SCHEMBL6070921 | 0.78 | CRHR1 (0.43) | CRHCRHR1 | |
| SCHEMBL6495917 | 0.77 | NPC1 (0.49) | CRHR1 | |
| SCHEMBL6071090 | 0.76 | CRHR1 (0.42) | CRHCRHR1 | |
| SCHEMBL7052095 | 0.72 | NPC1 (0.48) | CRHR1 | |
| SCHEMBL6497952 | 0.71 | CRHR1 (0.41) | CRHCRHR1 | |
| SCHEMBL6070738 | 0.71 | CRHR1 (0.45) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026317-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRH 3/4885CRHR1 1/4885 |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRH 3/4885CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.